Keywords: bad, news, amgen, fda, reviews, new, data

More bad news for Amgen and J&J as US FDA reviews new data on ESA risks

Article | 14 January 2008

Print This

In yet another piece of negative news for US drug major Johnson & Johnson and biotechnology giant Amgen, which could further ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in